Results 121 to 130 of about 2,249 (191)

Letter to the Editor Regarding "Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo Adjusted Indirect Treatment Comparison". [PDF]

Dermatol Ther (Heidelb)
Chovatiya R, Seminario-Vidal L, Gallo G, Ding Y, Yang C, Akmaz B, Solé-Feu L, Rand K.   +7 more
europepmc   +1 more source

The Effect of Lebrikizumab on Inflammatory Biomarkers in Patients with Asthma

US Respiratory & Pulmonary Diseases, 2023
openaire   +1 more source

Comparing the Efficacy and Safety of Nemolizumab Versus Anti-interleukin Monoclonal Antibody Therapies in Combination with Topical Treatments for Moderate-to-Severe Atopic Dermatitis Using Network Meta-analysis. [PDF]

Dermatol Ther (Heidelb)
Pink AE, Houghton J, White H, Schiavo S, Piketty C, Ulianov L, Rout R, Jack K, Subramanian R, Puelles J.   +9 more
europepmc   +1 more source

A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'". [PDF]

Dermatol Ther (Heidelb)
Ständer S, Pinter A, Hougeir FG, Guyot P, Xu Y, Praestgaard AH, Freemantle N, Rossi AB, Bégo-Le-Bagousse G, Wang Z, Noonan K, Bastian M.   +11 more
europepmc   +1 more source

Comparative efficacy and safety of biologic therapies in pediatric asthma: a comprehensive systematic review. [PDF]

Front Med (Lausanne)
Alzayed A.
europepmc   +1 more source

Is allergic sensitization relevant in severe asthma? Which allergens may be culprits? [PDF]

, 2017

core   +1 more source

FDA approval of EBGLYSS™ (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis in adults and children aged 12 and older. [PDF]

Ann Med Surg (Lond)
Khan MS, Siddiqui E, Khalid M, Bisimwa J, Akilimali A.   +4 more
europepmc   +1 more source

Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis

Lebrikizumab is a novel, high-affinity monoclonal antibody that selectively binds to interleukin (IL)-13. Objectives: To evaluate the efficacy and safety of lebrikizumab monotherapy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) over 52 weeks of treatment in ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967).
Blauvelt, Andrew||, Thyssen, Jacob Pontoppidan, Guttman-Yassky, Emma, Bieber, Thomas||, Serra-Baldrich, E||, Simpson, Eric L.||, Rosmarin, David M., Elmaraghy, Hany, Meskimen, Eric, Natalie, Chitra R., Liu, Zhuqing, Xu, Chenjia, Pierce, Evangeline J., Morgan-Cox, Mary Ann, García-Gil, Esther, Silverberg, Jonathan||   +15 more
openaire   +1 more source

Letter: Lebrikizumab for Refractory Atopic Dermatitis

Dermatitis®
Natalia V, Chalupczak, Peter, Lio
openaire   +2 more sources

<i>In vitro</i> potency and pharmacokinetics of APG777, a novel anti-IL-13 mAb. [PDF]

J Allergy Clin Immunol Glob
Zhu E, Prentice H, Oh J, Shaheen H, Gandhi NA, Wickman G, Dabora R, Dambkowski CL, Dillinger L.   +8 more
europepmc   +1 more source